Pusztai L - Search Results

1

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L. Coutant C, et al. Among authors: pusztai l. Clin Cancer Res. 2011 Apr 15;17(8):2591-601. doi: 10.1158/1078-0432.CCR-10-1045. Epub 2011 Jan 19. Clin Cancer Res. 2011. PMID: 21248301

2

Discouraging news for high-dose chemotherapy in high-risk breast cancer.

Pusztai L, Hortobagyi GN. Pusztai L, et al. Lancet. 1998 Aug 15;352(9127):501-2. doi: 10.1016/S0140-6736(05)79310-7. Lancet. 1998. PMID: 9716049 No abstract available.

3

Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.

Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Pusztai L, et al. Am J Clin Oncol. 1998 Oct;21(5):442-6. doi: 10.1097/00000421-199810000-00004. Am J Clin Oncol. 1998. PMID: 9781596 Clinical Trial.

4

Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.

Pusztai L, Holmes FA, Fraschini G, Hortobagyi GN. Pusztai L, et al. Cancer Chemother Pharmacol. 1999;43(1):86-91. doi: 10.1007/s002800050867. Cancer Chemother Pharmacol. 1999. PMID: 9923546 Clinical Trial.

5

Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer.

Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Pusztai L, et al. Breast Cancer Res Treat. 1999 May;55(1):1-8. doi: 10.1023/a:1006161906667. Breast Cancer Res Treat. 1999. PMID: 10472774

6

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

7

Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.

Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese JL. Madden T, et al. Among authors: pusztai l. Clin Cancer Res. 2000 Apr;6(4):1293-301. Clin Cancer Res. 2000. PMID: 10778954 Clinical Trial.

8

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Esteva FJ, et al. Among authors: pusztai l. Oncologist. 2001;6(2):133-46. doi: 10.1634/theoncologist.6-2-133. Oncologist. 2001. PMID: 11306725 Free article. Review.

9

Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Esteva FJ, et al. Among authors: pusztai l. Pathol Oncol Res. 2001;7(3):171-7. doi: 10.1007/BF03032345. Pathol Oncol Res. 2001. PMID: 11692142 Free article.

10

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.

Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Buchholz TA, et al. Among authors: pusztai l. Cancer J. 2001 Sep-Oct;7(5):413-20. Cancer J. 2001. PMID: 11693900

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

571 results

Search Page

Filters